**Condensed Consolidated Financial Statements** as of and for the Three and Nine Months Ended 31 December 2022

# James Hardie Industries plc Index

_	Page
Condensed Consolidated Balance Sheets as of 31 December 2022 and 31 March 2022	<u>F-3</u>
Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended 31 December 2022 and 2021	<u>F-4</u>
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended 31 December 2022 and 2021	<u>F-5</u>
Condensed Consolidated Statements of Changes in Shareholders' Equity for the Three and  Nine Months Ended 31 December 2022 and 2021	<u>F-6</u>
Notes to Condensed Consolidated Financial Statements	F-8

## James Hardie Industries plc Condensed Consolidated Balance Sheets

(Millions of US dollars)	(I 31	Jnaudited) December 2022		31 March 2022
Assets				
Current assets:				
Cash and cash equivalents	\$	110.0	\$	125.0
Restricted cash and cash equivalents		5.0		5.0
Restricted cash and cash equivalents - Asbestos		28.4		141.9
Restricted short-term investments - Asbestos		122.0		119.7
Accounts and other receivables, net		286.2		398.4
Inventories		371.4		279.7
Prepaid expenses and other current assets		67.7		43.2
Insurance receivable - Asbestos		7.2		7.9
Workers' compensation - Asbestos		2.9		3.2
Total current assets		1,000.8		1,124.0
Property, plant and equipment, net		1,744.2		1,457.0
Operating lease right-of-use-assets		57.6		57.8
Finance lease right-of-use-assets		2.3		2.3
Goodwill		190.3		199.5
Intangible assets, net		152.7		162.8
Restricted long-term investments - Asbestos		56.9		_
Insurance receivable - Asbestos		29.9		37.8
Workers' compensation - Asbestos		16.8		18.6
Deferred income taxes		753.5		819.2
Deferred income taxes - Asbestos		295.1		360.1
Other assets		7.5		4.1
Total assets	\$	4,307.6	\$	4,243.2
Liabilities and Shareholders' Equity				
Current liabilities:				
Accounts payable and accrued liabilities	\$	396.5	\$	458.0
Accrued payroll and employee benefits		91.2		116.6
Operating lease liabilities		17.8		12.5
Finance lease liabilities		0.9		1.1
Accrued product warranties		5.2		6.7
Income taxes payable		15.6		9.5
Asbestos liability		120.4		132.9
Workers' compensation - Asbestos		2.9		3.2
Other liabilities		25.0		29.4
Total current liabilities		675.5		769.9
Long-term debt		988.1		877.3
Deferred income taxes		91.2		86.9
Operating lease liabilities		60.1		63.1
Finance lease liabilities		1.5		1.5
Accrued product warranties		31.4		31.0
Income taxes payable		2.3		2.3
Asbestos liability		826.1		1,010.8
Workers' compensation - Asbestos		16.8		18.6
Other liabilities		46.9		48.9
Total liabilities		2,739.9	_	2,910.3
Commitments and contingencies (Note 8)		<u> </u>		<u> </u>
Shareholders' equity:				
Common stock, Euro 0.59 par value, 2.0 billion shares authorized; 444,246,402 shares issued and outstanding at 31 December 2022 and 445,348,933 shares issued and outstanding at 31 March 2022		231.4		232.1
Additional paid-in capital		232.8		230.4
Retained earnings		1,160.1		892.4
Accumulated other comprehensive loss		(56.6)		(22.0
Total shareholders' equity		1,567.7		1,332.9
		4,307.6	\$	4,243.2

## James Hardie Industries plc Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

	Three Months Ended 31 December					Nine N Ended 31		
(Millions of US dollars, except per share data)		2022		2021		2022		2021
Net sales	\$	860.8	\$	900.0	\$	2,859.3	\$	2,646.5
Cost of goods sold		571.2		577.5		1,877.3	_	1,687.3
Gross profit		289.6		322.5		982.0		959.2
Selling, general and administrative expenses		115.1		109.0		361.3		342.3
Research and development expenses		9.4		9.7		29.4		27.5
Asbestos adjustments loss (gain)		2.2		1.6		(19.5)	_	(10.8)
Operating income		162.9		202.2		610.8		600.2
Interest, net		7.0		10.6		24.0		30.8
Other (income) expense		(0.1)				(12.4)		0.1
Income before income taxes		156.0		191.6		599.2		569.3
Income tax expense		55.9		56.2		168.6		162.4
Net income	\$	100.1	\$	135.4	\$	430.6	\$	406.9
Income per share:								
Basic	\$	0.22	\$	0.30	\$	0.97	\$	0.91
Diluted	\$	0.22	\$	0.30	\$	0.97	\$	0.91
Weighted average common shares outstanding (Millions):								
Basic		445.4		445.2		445.4		444.7
Diluted		445.9		446.3		445.9		446.1
Comprehensive income, net of tax:								
Net income	\$	100.1	\$	135.4	\$	430.6	\$	406.9
Currency translation adjustments		30.4		(1.0)		(34.6)		(19.6)
Comprehensive income	\$	130.5	\$	134.4	\$	396.0	\$	387.3

## James Hardie Industries plc Condensed Consolidated Statements of Cash Flows (Unaudited)

(Millions of US dollars)	Nin	e Months End 2022	led 3	1 December 2021
Cash Flows From Operating Activities				
Net income	\$	430.6	\$	406.9
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization		126.6		119.5
Lease expense		16.4		16.4
Deferred income taxes		66.5		78.9
Stock-based compensation		9.3		12.9
Asbestos adjustments gain		(19.5)		(10.8)
Excess tax benefits from share-based awards		(0.2)		(3.2)
Gain on sale of land		(12.7)		
Other, net		15.0		13.4
Changes in operating assets and liabilities:				
Accounts and other receivables		99.5		1.4
Inventories		(99.3)		(54.8)
Lease assets and liabilities, net		(12.6)		(15.5)
Prepaid expenses and other assets		(29.0)		0.8
Insurance receivable - Asbestos		4.3		6.6
Accounts payable and accrued liabilities		(54.4)		33.5
Claims and handling costs paid - Asbestos		(90.2)		(92.0)
Income taxes payable		5.9		6.6
Other accrued liabilities		(24.1)		32.7
Net cash provided by operating activities	\$	432.1	\$	553.3
Cash Flows From Investing Activities				
Purchases of property, plant and equipment	\$	(450.7)	\$	(174.5)
Proceeds from sale of property, plant and equipment		14.1		_
Capitalized interest		(4.4)		(1.2)
Purchase of restricted investments - Asbestos		(76.4)		(21.8)
Proceeds from restricted investments - Asbestos				26.1
Net cash used in investing activities	\$	(517.4)	\$	(171.4)
Cash Flows From Financing Activities				
Proceeds from credit facilities	\$	270.0	\$	320.0
Repayments of credit facilities		(140.0)		(270.0)
Debt issuance costs		_		(2.1)
Proceeds from issuance of shares		0.1		0.2
Repayment of finance lease obligations and borrowings		(0.8)		(0.8)
Shares repurchased		(31.2)		_
Dividends paid		(129.6)		(461.8)
Taxes paid related to net share settlement of equity awards		(5.8)		(2.8)
Net cash used in financing activities	\$	(37.3)	\$	(417.3)
Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos	\$	(5.9)	\$	(7.4)
Net decrease in cash and cash equivalents, restricted cash and restricted cash - Asbestos		(128.5)		(42.8)
Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period		271.9		318.4
Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period	\$	143.4	\$	275.6
Non-Cash Investing and Financing Activities				
Capital expenditures incurred but not yet paid	\$	36.0	\$	34.9
Supplemental Disclosure of Cash Flow Activities				
Cash paid to AICF	\$	54.8	\$	124.2

## James Hardie Industries plc Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited)

		Three Months Ended 31 December 2022											
(Millions of US dollars)	Additional Common Paid-in Stock Capital				Retained Earnings		Treasury Stock		ccumulated Other nprehensive Loss		Total		
Balances as of 30 September 2022	\$	232.3	\$	231.7	\$	1,089.3	\$	_	\$	(87.0)	\$	1,466.3	
Net income		_		_		100.1		_		_		100.1	
Other comprehensive income		_		_		_		_		30.4		30.4	
Stock-based compensation		0.1		2.0		_		_		_		2.1	
Shares repurchased		_		_		_		(31.2)		_		(31.2)	
Shares cancelled		(1.0)		(0.9)		(29.3)		31.2					
Balances as of 31 December 2022	\$	231.4	\$	232.8	\$	1,160.1	\$	_	\$	(56.6)	\$	1,567.7	

	Nine Months Ended 31 December 2022											
(Millions of US dollars)	(	Common Stock	,	Additional Paid-in Capital		Retained Earnings		Treasury Stock		ocumulated Other nprehensive Loss		Total
Balances as of 31 March 2022	\$	232.1	\$	230.4	\$	892.4	\$		\$	(22.0)	\$	1,332.9
Net income		_		_		430.6		_		_		430.6
Other comprehensive loss		_		_		_		_		(34.6)		(34.6)
Stock-based compensation		0.3		3.2		_		_		_		3.5
Issuance of ordinary shares		_		0.1		_		_		_		0.1
Dividends declared		_		_		(133.6)		_		_		(133.6)
Shares repurchased		_		_		_		(31.2)		_		(31.2)
Shares cancelled		(1.0)		(0.9)		(29.3)		31.2				_
Balances as of 31 December 2022	\$	231.4	\$	232.8	\$	1,160.1	\$		\$	(56.6)	\$	1,567.7

		Three Months Ended 31 December 2021													
(Millions of US dollars)	Additional Common Paid-in Stock Capital					Retained Earnings		ccumulated Other mprehensive Loss		Total					
Balances as of 30 September 2021	\$	232.0	\$	232.0	\$	882.9	\$	(25.2)	\$	1,321.7					
Net income		_		_		135.4		_		135.4					
Other comprehensive loss		_		_		_		(1.0)		(1.0)					
Stock-based compensation		0.1		2.1		_		_		2.2					
Issuance of ordinary shares		_		0.1		_		_		0.1					
Dividends declared						(178.1)		_		(178.1)					
Balances as of 31 December 2021	\$	232.1	\$	234.2	\$	840.2	\$	(26.2)	\$	1,280.3					

## James Hardie Industries plc Condensed Consolidated Statements of Changes in Shareholders' Equity (continued) (Unaudited)

(			Nine Mor	nths	Ended 31 Decem	ber 2021			
(Millions of US dollars)	Additional Accumulated Other Common Paid-in Retained Comprehensive Stock Capital Earnings Loss								Total
Balances as of 31 March 2021	\$ 231.4	\$	224.6	\$	611.4	\$ (6.	6)	\$	1,060.8
Net income	_		_		406.9	_	_		406.9
Other comprehensive loss	_		_		_	(19.	6)		(19.6)
Stock-based compensation	0.7		9.4		_	-	_		10.1
Issuance of ordinary shares	_		0.2		_	-	_		0.2
Dividends declared					(178.1)				(178.1)
Balances as of 31 December 2021	\$ 232.1	\$	234.2	\$	840.2	\$ (26.	2)	\$	1,280.3

### 1. Organization and Significant Accounting Policies

### **Nature of Operations**

James Hardie Industries plc ("JHI plc") manufactures and sells fiber cement, fiber gypsum and cement-bonded building products for interior and exterior building construction applications, primarily in the United States, Australia, Europe, New Zealand and the Philippines.

#### **Basis of Presentation**

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the U.S. generally accepted accounting principles ("GAAP") for interim financial information. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto, included in the Company's Annual Report on Form 20-F for the fiscal year ended 31 March 2022 from which the prior year balance sheet information herein was derived. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expense, and related disclosures. Actual results could differ from those estimates.

The condensed consolidated financial statements represent the financial position, results of operations and cash flows of JHI plc and its wholly-owned subsidiaries and variable interest entity ("VIE"). Unless the context indicates otherwise, JHI plc and its direct and indirect wholly-owned subsidiaries and VIE (as of the time relevant to the applicable reference) are collectively referred to as "James Hardie", the "James Hardie Group" or the "Company". All intercompany balances and transactions have been eliminated in consolidation. In management's opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation of the results for the interim periods presented.

The Company has recorded on its condensed consolidated balance sheets certain foreign assets and liabilities, including asbestos related assets and liabilities under the terms of the Amended and Restated Final Funding Agreement ("AFFA"), that are denominated in foreign currencies and subject to translation (foreign entities) or remeasurement (Asbestos Injuries Compensation Fund ("AICF") entity and Euro denominated debt) into US dollars at each reporting date. Unless otherwise noted, the Company converts foreign currency denominated assets and liabilities into US dollars at the current spot rate at the end of the reporting period; while revenues and expenses are converted using an average exchange rate for the period. The Company records gains and losses on its Euro denominated debt which are economically offset by foreign exchange gains and losses on loans between subsidiaries, resulting in a net immaterial translation gain or loss which is recorded in the Selling, general and administrative expenses in the condensed consolidated statements of operations and comprehensive income.

#### **Summary of Significant Accounting Policies**

During the first quarter of fiscal year 2023, the Company reclassified its Restricted Short-Term Investments - Asbestos from available for sale to held to maturity ("HTM") due to AICF's ability and intent to hold these securities to maturity. At the time of the reclassification, the fair value of the investments were carried at fair value. Subsequently, these investments are carried at amortized cost.

Other than noted above, there were no changes to our significant accounting policies as described in our Annual Report on Form 20-F for the fiscal year ended 31 March 2022.

## Notes to Condensed Consolidated Financial Statements (continued)

### **Earnings Per Share**

Basic earnings per share ("EPS") is calculated using net income divided by the weighted average number of common shares outstanding during the period. Diluted EPS is similar to basic EPS except that the weighted average number of common shares outstanding is increased to include the number of additional common shares calculated using the treasury method that would have been outstanding if the dilutive potential common shares, such as restricted stock units, had been issued.

Basic and dilutive common shares outstanding used in determining net income per share are as follows:

	Three Months Ended 31 December						
(Millions of shares)	2022	2021	2022	2021			
Basic common shares outstanding	445.4	445.2	445.4	444.7			
Dilutive effect of stock awards	0.5	1.1	0.5	1.4			
Diluted common shares outstanding	445.9	446.3	445.9	446.1			

There were no potential common shares which would be considered anti-dilutive for the three and nine months ended 31 December 2022 and 2021.

Potential common shares of 0.7 million and 0.4 million for the three and nine months ended 31 December 2022, respectively and 0.6 million and 0.5 million for the three and nine months ended 31 December 2021, respectively, have been excluded from the calculation of diluted common shares outstanding as they are considered contingent shares which are not expected to vest.

#### 2. Revenues

The following represents the Company's disaggregated revenues:

	Three Months Ended 31 December 2022									
(Millions of US dollars)		America Cement		sia Pacific per Cement	Eu	rope Building Products	Сс	nsolidated		
Fiber cement revenues	\$	645.4	\$	112.3	\$	14.5	\$	772.2		
Fiber gypsum revenues		_		_		88.6		88.6		
Total revenues	\$	645.4	\$	112.3	\$	103.1	\$	860.8		
		Thi	ree N	Months Ende	ed 31	1 December 20	021			
(Millions of US dollars)		America Cement		sia Pacific per Cement	Eu	rope Building Products	Сс	nsolidated		
Fiber cement revenues	\$	644.9	\$	143.3	\$	15.8	\$	804.0		
Fiber gypsum revenues		_		_		96.0		96.0		
Total revenues	\$	644.9	\$	143.3	\$	111.8	\$	900.0		
	North	Nii America		fonths Ended		December 20	22			
(Millions of US dollars)		Cement		er Cement	Lu	Products	Co	nsolidated		
Fiber cement revenues	\$	2,136.1	\$	399.4	\$	50.1	\$	2,585.6		
Fiber gypsum revenues		_		_		273.7		273.7		
Total revenues	\$	2,136.1	\$	399.4	\$	323.8	\$	2,859.3		

## Notes to Condensed Consolidated Financial Statements (continued)

	Nii	ne M	onths Ended	d 31	December 20	21	
(Millions of US dollars)	 n America r Cement		sia Pacific er Cement	Εu	rope Building Products	С	onsolidated
Fiber cement revenues	\$ 1,857.3	\$	429.5	\$	57.7	\$	2,344.5
Fiber gypsum revenues					302.0		302.0
Total revenues	\$ 1,857.3	\$	429.5	\$	359.7	\$	2,646.5

The process by which the Company recognizes revenues is similar across each of the Company's reportable segments. Fiber cement and fiber gypsum revenues are primarily generated from the sale of siding and various boards used in external and internal applications, as well as accessories. Fiber gypsum revenues also includes the sale of cement-bonded boards in the Europe Building Products segment.

### 3. Cash and Cash Equivalents, Restricted Cash and Restricted Cash - Asbestos

The following table provides a reconciliation of *Cash and cash equivalents, Restricted cash and Restricted cash - Asbestos* reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:

	31	December	31 March
(Millions of US dollars)		2022	2022
Cash and cash equivalents	\$	110.0	\$ 125.0
Restricted cash		5.0	5.0
Restricted cash - Asbestos		28.4	 141.9
Total cash and cash equivalents, restricted cash and restricted cash - Asbestos	\$	143.4	\$ 271.9

Restricted cash relates to an insurance policy which restricts the cash from general corporate purposes.

Restricted cash - Asbestos is restricted to the settlement of asbestos claims and for the payment of the operating costs of AICF.

#### 4. Inventories

*Inventories* consist of the following components:

	31 🛭	December	31 March
(Millions of US dollars)		2022	2022
Finished goods	\$	264.8	\$ 187.3
Work-in-process		21.1	16.2
Raw materials and supplies		93.9	82.1
Provision for obsolete finished goods and raw materials		(8.4)	(5.9)
Total inventories	\$	371.4	\$ 279.7

## **Notes to Condensed Consolidated Financial Statements (continued)**

### 5. Long-Term Debt

(Millions of US dollars)	31	December 2022	31 March 2022
Senior unsecured notes:			
Principal amount 3.625% notes due 2026 (€400.0 million)	\$	425.7	\$ 446.4
Principal amount 5.000% notes due 2028		400.0	 400.0
Total		825.7	846.4
Unsecured revolving credit facility		170.0	40.0
Unamortized debt issuance costs:		(7.6)	 (9.1)
Total Long-term debt	\$	988.1	\$ 877.3
Weighted average interest rate of Long-term debt		4.6 %	4.2 %
Weighted average term of available Long-term debt		4.2 years	5.0 years
Fair value of Senior unsecured notes (Level 1)	\$	766.9	\$ 845.1

As of 31 December 2022, the Company had a total borrowing base capacity under the revolving credit facility of US\$600.0 million with outstanding borrowings of US\$170.0 million, and US\$7.4 million of issued but undrawn letters of credit and bank guarantees. These letters of credit and bank guarantees relate to various operational matters including insurance, performance bonds and other items, leaving the Company with US\$422.6 million of available borrowing capacity under the revolving credit facility.

At 31 December 2022, the Company was in compliance with all of its covenants contained in the senior unsecured notes and the unsecured revolving credit facility agreement.

#### 6. Asbestos

In February 2007, the Company's shareholders approved the AFFA, an agreement pursuant to which the Company provides long-term funding to AICF.

#### Asbestos Adjustments Loss (Gain)

The Asbestos adjustments loss (gain) included in the condensed consolidated statements of operations and comprehensive income comprise the following:

	Three I Ended 31		Nine M Ended 31	
(Millions of US dollars)	2022	2021	2022	2021
Effect of foreign exchange on Asbestos net liabilities	\$ 16.4	\$ 3.5	\$ (42.7)	\$ (24.4)
(Gain) loss on foreign currency forward contracts	(13.4)	(2.3)	21.8	14.3
Other	(8.0)	0.4	1.4	(0.7)
Asbestos adjustments loss (gain)	\$ 2.2	\$ 1.6	\$ (19.5)	\$ (10.8)

#### Claims Data

The following table shows the activity related to the numbers of open claims, new claims and closed claims during each of the past five years and the average settlement per settled claim and case closed:

	Nine Months					
	Ended			Years Ended 3	1 March	
	31 December 2022	2022	2021	2020	2019	2018
Number of open claims at beginning of period	365	360	393	332	336	352
Number of new claims						
Direct claims	302	411	392	449	430	422
Cross claims	121	144	153	208	138	140
Number of closed claims	450	550	578	596	572	578
Number of open claims at end of period	338	365	360	393	332	336
Average settlement amount per settled claim	A\$305,000	A\$314,000	A\$248,000	A\$277,000	A\$262,000	A\$253,000
Average settlement amount per case closed <sup>1</sup>	A\$272,000	A\$282,000	A\$225,000	A\$245,000	A\$234,000	A\$217,000
Average settlement amount per settled claim	US\$209,000	US\$232,000	US\$178,000	US\$189,000	US\$191,000	US\$196,000
Average settlement amount per case closed <sup>1</sup>	US\$186,000	US\$208,000	US\$162,000	US\$167,000	US\$171,000	US\$168,000

<sup>&</sup>lt;sup>1</sup> The average settlement amount per case closed includes nil settlements.

Under the terms of the AFFA, the Company has rights of access to actuarial information produced for AICF by the actuary appointed by AICF, which is currently KPMG Actuarial. The Company's disclosures with respect to claims statistics are subject to it obtaining such information, however, the AFFA does not provide the Company an express right to audit or otherwise require independent verification of such information or the methodologies to be adopted by the approved actuary. As such, the Company relies on the accuracy and completeness of the information provided by AICF to the approved actuary and the resulting information and analysis of the approved actuary when making disclosures with respect to claims statistics.

The following is a detailed rollforward of the Net Unfunded AFFA liability, net of tax, for the nine months ended 31 December 2022:

(Millions of US dollars)	Asbestos Liability	Insurance Receivables	Restricted Cash and Investments	Other Assets and Liabilities	Net Unfunded AFFA Liability	Deferred Tax Assets	Income Tax Payable	Net Unfunded AFFA Liability, net of tax
Opening Balance - 31 March 2022	\$ (1,143.7)	\$ 45.7	\$ 261.6	\$ (1.1)	\$ (837.5)	\$ 360.1	\$ 43.9	\$ (433.5)
Asbestos claims paid <sup>1</sup>	89.4	_	(89.4)	_	_	_	_	_
Payment received in accordance with AFFA	_	_	54.8	_	54.8	_	_	54.8
AICF claims-handling costs incurred (paid)	0.8	_	(0.8)	_	_	_	_	_
AICF operating costs paid - non claims-handling	_	_	(1.0)	_	(1.0)	_	_	(1.0)
Insurance recoveries	_	(4.3)	4.3	_	_	_	_	_
Movement in income tax payable	_	_	_	_	_	(30.8)	(9.3)	(40.1)
Other movements	_	_	0.7	(0.5)	0.2	(0.5)	_	(0.3)
Effect of foreign exchange	107.0	(4.3)	(22.9)	0.7	80.5	(33.7)	(4.1)	42.7
Closing Balance - 31 December 2022	\$ (946.5)	\$ 37.1	\$ 207.3	\$ (0.9)	\$ (703.0)	\$ 295.1	\$ 30.5	\$ (377.4)

## Notes to Condensed Consolidated Financial Statements (continued)

1 Claims paid of US\$89.4 million reflects A\$130.8 million converted at the average exchange rate for the period based on the assumption that these transactions occurred evenly throughout the period.

#### AICF Funding

During fiscal year 2023, the Company will contribute A\$160.4 million to AICF in quarterly installments. Total payments of A\$119.8 million have been made through 3 January 2023.

For the nine months ended 31 December 2022, the Company did not provide financial or other support to AICF that it was not previously contractually required to provide.

#### Restricted Investments

AICF invests its excess cash in time deposits, which are classified as HTM investments and the carrying value materially approximates the fair value for each investment. The following table represents the investments entered into as of 31 December 2022:

Date Invested	Maturity Date	Interest Rate	A\$ Millions
August 2022	15 February 2023	3.35%	50.0
April 2022	5 April 2024	2.75%	54.0
January 2022	25 January 2024	1.41%	30.0
January 2022	25 January 2023	0.79%	100.0
October 2021	6 October 2023	0.60%	30.0

#### 7. Derivative Instruments

The Company uses derivatives for risk management purposes and does not engage in speculative activity. A risk management objective for the Company is to mitigate interest rate risk associated with the Company's external credit facilities and foreign currency risk primarily with respect to forecasted transactions denominated in foreign currencies. The determination of whether the Company enters into a derivative transaction to achieve these risk management objectives depends on a number of factors, including an evaluation of the extent to which derivative instruments will achieve such risk management objectives of the Company.

#### Foreign Currency Forward Contracts

The Company's foreign currency forward contracts are valued using models that maximize the use of market observable inputs including interest rate curves and both forward and spot prices for currencies and are categorized as Level 2 within the fair value hierarchy.

The following table sets forth the total outstanding notional amount and the fair value of the Company's foreign currency forward contracts:

							ue	as of				
(Millions of US dollars)		<b>Notional Amount</b>				31 Decer	r 2022	31 March 2022				
Derivatives not accounted for as hedges		ecember 2022		31 March 2022	Assets		Liabilities			Assets		Liabilities
Foreign currency forward contracts	\$	293.0	\$	251.0	\$	2.4	\$	10.3	\$	2.0	\$	1.9

## Notes to Condensed Consolidated Financial Statements (continued)

The following table sets forth the gain and loss on the Company's foreign currency forward contracts recorded in the Company's condensed consolidated statements of operations and comprehensive income as follows:

	Three I Ended 31		Nine N Ended 31	 	
(Millions of US dollars)	2022		2021	2022	2021
Asbestos adjustments (gain) loss	\$ (13.4)	\$	(2.3)	\$ 21.8	\$ 14.3
Selling, general and administrative (income) expenses	(0.6)		3.6	4.0	(2.0)
Total (gain) loss	\$ (14.0)	\$	1.3	\$ 25.8	\$ 12.3

#### 8. Commitments and Contingencies

#### Legal Matters

The Company is involved from time to time in various legal proceedings and administrative actions related to the normal conduct of its business, including general liability claims, putative class action lawsuits and litigation concerning its products.

Although it is impossible to predict the outcome of any pending legal proceeding, management believes that such proceedings and actions should not, individually or in the aggregate, have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows, except as they relate to asbestos and New Zealand weathertightness claims as described in these condensed consolidated financial statements.

## New Zealand Weathertightness Claims

Since fiscal year 2002, the Company's New Zealand subsidiaries have been joined in a number of weathertightness claims in New Zealand that relate to residential buildings (single dwellings and apartment complexes) and a small number of non-residential buildings, primarily constructed from 1998 to 2004. The claims often involve multiple parties and allege that losses were incurred due to excessive moisture penetration of the buildings' structures. The claims typically include allegations of poor building design, inadequate certification of plans, inadequate construction review and compliance certification and deficient work by sub-contractors.

Historically, the Company's New Zealand subsidiaries have been joined to these claims as one of several co-defendants, including local government entities responsible for enforcing building codes and practices, resulting in the Company's New Zealand subsidiaries becoming liable for only a portion of each claim. In addition, the Company's New Zealand subsidiaries have had access to third-party recoveries to defray a portion of the costs incurred in resolving such claims.

Currently pending are two claims filed on behalf of multiple plaintiffs in 2015 against the Company and/or its subsidiaries as the sole defendants, each of which alleges that the New Zealand subsidiaries' products were inherently defective. The Company believes it has substantial factual and legal defenses to these claims and is defending the claims vigorously.

Cridge, et al. (Case Nos. CIV-2015-485-594 and CIV-2015-485-773), In the High Court of New Zealand, Wellington Registry (hereinafter the "Cridge litigation"). From August to December 2020, the trial of phase one of the Cridge litigation was held in Wellington, New Zealand solely to determine whether the Company's New Zealand subsidiaries had a duty to the plaintiffs and breached that duty. In August 2021, the Wellington High Court issued its decision finding in favor of the Company on all claims (the "Cridge Decision"). In September 2021, plaintiffs filed a notice of appeal of the trial court's decision, and

### Notes to Condensed Consolidated Financial Statements (continued)

subsequently the appellate court held a hearing in August 2022. The Company anticipates the appellate court will issue its decision during calendar year 2023. As of 31 December 2022, the Company has not recorded a reserve related to the Cridge litigation as the chance of loss remains not probable following the Cridge Decision.

Waitakere, et al. (Case No. CIV-2015-404-3080), In the High Court of New Zealand, Auckland Registry (hereinafter the "Waitakere litigation"). The trial in the Waitakere litigation is scheduled to begin May 2023 in Auckland, New Zealand. As of 31 December 2022, the Company has not recorded a reserve related to the Waitakere litigation as the chance of loss is not probable and the amount of loss, if any, cannot be reasonably estimated.

The resolution of one or more of the litigation matters by way of a court decision or settlement has the potential to impact the accounting treatment regarding the probability of a potential loss and the Company's ability to reasonably estimate a reserve with regards to the other litigation matters discussed above. Furthermore, an adverse judgement in one or more of these litigation matters could have a material adverse impact on our consolidated financial position, results of operations or cash flows.

#### **Environmental**

The operations of the Company, like those of other companies engaged in similar businesses, are subject to a number of laws and regulations on air, soil and water quality, waste handling and disposal. The Company's policy is to accrue for environmental costs when it is determined that it is probable that an obligation exists and the amount can be reasonably estimated.

#### 9. Income Taxes

*Income taxes payable* represents taxes currently payable which are computed at statutory income tax rates applicable to taxable income derived in each jurisdiction in which the Company conducts business. During the nine months ended 31 December 2022, the Company paid taxes, net of refunds, of US\$89.1 million.

*Income tax expense* differs from the statutory rate primarily due to the Company's mix of pre-tax income by jurisdiction, foreign taxes on domestic income and foreign exchange on asbestos.

Deferred income taxes include net operating loss carry-forwards. At 31 December 2022, the Company had tax loss carry-forwards in Australia, New Zealand, Europe and the US of approximately US\$70.3 million that are available to offset future taxable income in the respective jurisdiction. The Company establishes a valuation allowance against a deferred tax asset if it is more likely than not that some portion or all of the deferred tax asset will not be realized.

The Australian tax loss carry-forwards primarily result from current and prior year tax deductions for contributions to AICF. James Hardie 117 Pty Limited, the performing subsidiary under the AFFA, is able to claim a tax deduction for its contributions to AICF over a five-year period commencing in the year the contribution is incurred. At 31 December 2022, the Company recognized a tax deduction of US\$103.1 million (A\$150.4 million) for the current year relating to total contributions to AICF of US\$722.5 million (A\$1,002.8 million) incurred in tax years 2019 through 2023.

### 10. Stock-Based Compensation

Total stock-based compensation expense consists of the following:

	Three Ended 31		Nine N Ended 31			
(Millions of US dollars)	2022		2021		2022	2021
Liability Awards	\$ 0.5	\$	(0.3)	\$	_	\$ 8.2
Equity Awards	3.8		2.2		9.3	12.9
Total stock-based compensation expense	\$ 4.3	\$	1.9	\$	9.3	\$ 21.1

As of 31 December 2022, the unrecorded future stock-based compensation expense related to outstanding equity awards was US\$33.1 million and will be recognized over an estimated weighted average amortization period of 2.1 years.

## 11. Segment Information

The Company reports its operating segment information in the format that the operating segment information is available to and evaluated by the Chief Operating Decision Maker. The North America Fiber Cement segment manufactures fiber cement interior linings, exterior siding products and related accessories in the United States; these products are sold in the United States and Canada. The Asia Pacific Fiber Cement segment includes all fiber cement products manufactured in Australia and the Philippines, and sold in Australia, New Zealand, Asia, the Middle East and various Pacific Islands. The Europe Building Products segment includes fiber gypsum and cement-bonded boards manufactured in Europe and fiber cement product manufactured in the United States that is sold in Europe. The Research and Development segment represents the cost incurred by the research and development centers. General Corporate primarily consist of Asbestos adjustments loss (gain), officer and employee compensation and related benefits, professional and legal fees, administrative costs and rental expense on the Company's corporate offices. The Company does not report net interest expense for each segment as the segments are not held directly accountable for interest expense.

### **Operating Segments**

The following is the Company's operating segment information:

			Net Sales								
	Three Months Ended 31 December										
(Millions of US dollars)		2022		2021		2022		2021			
North America Fiber Cement	\$	645.4	\$	644.9	\$	2,136.1	\$	1,857.3			
Asia Pacific Fiber Cement		112.3		143.3		399.4		429.5			
Europe Building Products		103.1		111.8		323.8		359.7			
Worldwide total	\$	860.8	\$	900.0	\$	2,859.3	\$	2,646.5			
				Operation	a Inc	nomo					

	Operating Income									
		Three Months Ended 31 December				Nine N Ended 31				
(Millions of US dollars)		2022		2021		2022	2021			
North America Fiber Cement	\$	174.1	\$	183.3	\$	578.7	\$	535.1		
Asia Pacific Fiber Cement		27.6		39.1		102.5		122.4		
Europe Building Products		1.4		11.9		18.0		44.9		
Research and Development		(7.8)		(8.5)		(25.3)		(25.2)		
Segments total		195.3		225.8		673.9		677.2		
General Corporate		(32.4)		(23.6)		(63.1)		(77.0)		
Total operating income	\$	162.9	\$	202.2	\$	610.8	\$	600.2		

Research and development expenditures are expensed as incurred and are summarized by segment in the following table. For the three and nine months ended 31 December 2022, Research and development segment operating income also includes *Selling, general and administrative expenses* of US\$0.4 million and US\$1.6 million, respectively. For the three and nine months ended 31 December 2021, Research and development segment operating income also includes *Selling, general and administrative expenses* of US\$0.8 million and US\$3.3 million, respectively.

Research and Development Expenses										
					Nine Months Ended 31 December					
	2022		2021		2022		2021			
\$	1.3	\$	1.3	\$	3.5	\$	3.8			
	0.3		0.4		1.0		1.1			
	0.4		0.3		1.2		0.7			
	7.4		7.7		23.7		21.9			
\$	9.4	\$	9.7	\$	29.4	\$	27.5			
	\$	Three Ended 31 2022 \$ 1.3 0.3 0.4 7.4	Three Montl Ended 31 Dece 2022  \$ 1.3 \$ 0.3	Three Months Ended 31 December 2022 2021  \$ 1.3 \$ 1.3  0.3 0.4  0.4 0.3  7.4 7.7	Three Months Ended 31 December 2022 2021  \$ 1.3 \$ 1.3 \$  0.3 0.4  0.4 0.3  7.4 7.7	Three Months Ended 31 December 2022 2021 2022 \$ 1.3 \$ 1.3 \$ 3.5  0.3 0.4 1.0  0.4 0.3 1.2  7.4 7.7 23.7	Ended 31 December Ended 31 December 2022 2021 2022 2022 \$ 1.3 \$ 1.3 \$ 3.5 \$ 0.3 0.4 1.0 0.4 0.3 1.2 7.4 7.7 23.7			

### 12. Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss is comprised of the following at 31 December 2022:

(Millions of US dollars)	Cash Flow Hedges	A	Pension ctuarial Loss	Foreign Currency Translation Adjustments	Total
Balance at 31 March 2022	\$ 0.2	\$	(0.3)	\$ (21.9)	\$ (22.0)
Other comprehensive loss	_		<u> </u>	(34.6)	(34.6)
Balance at 31 December 2022	\$ 0.2	\$	(0.3)	\$ (56.5)	\$ (56.6)

## 13. Capital Management

On 8 November 2022, the Company announced a share buyback program to acquire up to US\$200 million of its outstanding shares through October 2023. Below is the activity under this program:

			Total Number of Shares Purchased	Maximum Dollar Value of Shares
		Average Price	as Part of	That May Yet be
	Total Number	Paid per	Publically	Purchased Under
	of Shares	Share	Announced	the Program
In Millions, except price per share	Purchased	(US\$)	Program	(US\$)
1 December 2022 - 31 December 2022	1.6	\$19.34	1.6	\$168.8

All shares repurchased were subsequently cancelled by the Company and are no longer available for issuance.